StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)

Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%

Castle Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Castle Biosciences's operating margin for the twelve months ending Sep 30, 2026 was -7.4%. For fiscal 2025 it was -12.4%, against 2.6% the year before. The highest annual figure on record is 14.1% in fiscal 2019.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-12.4%−15.0
FY2024Dec 31, 20242.6%+33.5
FY2023Dec 31, 2023-30.9%+22.2
FY2022Dec 31, 2022-53.2%−10.6
FY2021Dec 31, 2021-42.6%−32.2
FY2020Dec 31, 2020-10.4%−24.6
FY2019Dec 31, 201914.1%+31.0
FY2018Dec 31, 2018-16.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-2.7%+5.5
Q2 FY2026Jun 30, 2026-3.0%+2.0
Q1 FY2026Mar 31, 2026-22.0%+9.7
Q4 FY2025Dec 31, 2025-4.4%−9.1
Q3 FY2025Sep 30, 2025-8.2%−14.1
Q2 FY2025Jun 30, 2025-4.9%−10.7
Q1 FY2025Mar 31, 2025-31.7%−24.2
Q4 FY2024Dec 31, 20244.7%+13.2
Q3 FY2024Sep 30, 20245.9%+21.6
Q2 FY2024Jun 30, 20245.8%+48.0
Q1 FY2024Mar 31, 2024-7.5%+67.5
Q4 FY2023Dec 31, 2023-8.6%+51.0
Q3 FY2023Sep 30, 2023-15.7%+42.5
Q2 FY2023Jun 30, 2023-42.2%−30.8
Q1 FY2023Mar 31, 2023-75.0%+16.3
Q4 FY2022Dec 31, 2022-59.6%+1.0
Q3 FY2022Sep 30, 2022-58.2%−7.9
Q2 FY2022Jun 30, 2022-11.4%+27.3
Q1 FY2022Mar 31, 2022-91.3%−72.5
Q4 FY2021Dec 31, 2021-60.6%−43.1
Q3 FY2021Sep 30, 2021-50.3%−24.7
Q2 FY2021Jun 30, 2021-38.7%−33.6
Q1 FY2021Mar 31, 2021-18.8%−24.7
Q4 FY2020Dec 31, 2020-17.5%−32.3
Q3 FY2020Sep 30, 2020-25.6%−55.6
Q2 FY2020Jun 30, 2020-5.1%−10.7
Q1 FY2020Mar 31, 20205.9%+9.6
Q4 FY2019Dec 31, 201914.8%−26.9
Q3 FY2019Sep 30, 201930.0%+106.8
Q2 FY2019Jun 30, 20195.7%+72.7
Q1 FY2019Mar 31, 2019-3.7%–
Q4 FY2018Dec 31, 201841.7%–
Q3 FY2018Sep 30, 2018-76.8%–
Q2 FY2018Jun 30, 2018-67.0%–

More Castle Biosciences figures

See a number that looks wrong?